KKR, US48251W1045

KKR stock: Integer acquisition closes at $5.7 billion value

Published on 11/18/2026 at 13:53 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
KKR stock enters a new portfolio phase as its affiliate completes the Integer deal. The medical-device maker is moving into private ownership.

Integer joins KKR portfolio

  • KKR completed its acquisition of Integer Holdings through an affiliate of investment funds managed by the firm.
  • Integer shareholders received cash consideration, and the medical-device manufacturer ceased trading on the New York Stock Exchange.
  • KKR said it plans to support Integer's growth strategy, people, capabilities and technologies.
KKR, US48251W1045, Illustration mit AI erstellt.

On Tuesday, November 17, KKR completed its acquisition of Integer Holdings through an affiliate of investment funds managed by the firm, according to a GlobeNewswire release republished by Yahoo Finance. The transaction gives KKR control of a medical-device contract development and manufacturing company and adds another completed portfolio investment to its platform.

Integer said the transaction carries an enterprise value of approximately 5.7 billion US dollars. The deal was announced on August 3 and received approval from Integer shareholders on October 21. Under the terms, Integer shareholders receive 127 US dollars in cash for each share.

Integer leaves public markets

With the closing, Integer's common stock ceased trading and will no longer be listed on the New York Stock Exchange. The completion marks the end of the public-market phase of the company and transfers its future operating performance to KKR's private portfolio.

Integer develops and manufactures medical devices for customers in the cardio and vascular, neuromodulation, and cardiac rhythm management markets. Its brands include Greatbatch Medical and Lake Region Medical. The company describes itself as a strategic partner for medical-device companies and emerging innovators.

For KKR, the transaction broadens the portfolio's exposure to medical-device manufacturing rather than adding a listed equity holding. The company's release said Integer has opportunities to expand its capabilities and continue investing in people, technology and customer support. Those priorities point to operational development as the next stage after the acquisition closes.

Management outlines growth focus

Integer President and Chief Executive Officer Payman Khales said the company intends to accelerate its growth strategy and invest further in its workforce, capabilities and technologies. Max Lin, a KKR partner, said the firm sees opportunities to build on Integer's existing position in the medical-device industry alongside management.

The statements describe an ownership and operating plan rather than a new public earnings forecast. Investors in KKR will therefore look to future portfolio disclosures and financial reports for evidence of how the completed acquisition contributes to the firm's investment activity and results.

KKR stock traded at 86.54 euros on Lang & Schwarz at 13:43 CET on Wednesday, November 18.

KKR & Co. Inc.

  • Company: KKR & Co. Inc.
  • ISIN: US48251W1045
  • Ticker: KKR
  • Primary exchange: New York Stock Exchange
  • Lang & Schwarz quote: 86.54 euros on Wednesday, November 18, at 13:43 CET

In the broader US market, investors are watching the S&P 500 backdrop as private-equity firms continue to realize portfolio investments.

More news and analyses on KKR stock

Disclaimer...
en | US48251W1045 | KKR | boerse | 70530974 | bgmi